PCI Biotech Holding ASA (PCIB.OL)
NOK 1.32
(-0.75%)
NOK 1.32
(-0.75%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -40.86 Million NOK | 25.97% |
| 2022 | -55.19 Million NOK | 51.27% |
| 2021 | -113.27 Million NOK | 39.26% |
| 2020 | -186.49 Million NOK | 27.93% |
| 2019 | -258.78 Million NOK | 25.77% |
| 2018 | -348.62 Million NOK | -594.52% |
| 2017 | -50.19 Million NOK | -273.68% |
| 2016 | -13.43 Million NOK | 72.41% |
| 2015 | -48.68 Million NOK | -220.7% |
| 2014 | -15.18 Million NOK | 67.07% |
| 2013 | -46.1 Million NOK | 36.51% |
| 2012 | -72.62 Million NOK | 22.17% |
| 2011 | -93.31 Million NOK | 13.84% |
| 2010 | -108.3 Million NOK | -202.33% |
| 2009 | -35.82 Million NOK | 28.56% |
| 2008 | -50.14 Million NOK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -30.53 Million NOK | 1.56% |
| 2024 Q1 | -30.53 Million NOK | 25.28% |
| 2023 Q1 | -50.45 Million NOK | 8.6% |
| 2023 Q3 | -41.18 Million NOK | 8.49% |
| 2023 Q2 | -45 Million NOK | 10.79% |
| 2023 FY | -40.86 Million NOK | 25.97% |
| 2023 Q4 | -40.86 Million NOK | 0.77% |
| 2022 Q2 | -74.73 Million NOK | 18.7% |
| 2022 Q4 | -55.19 Million NOK | 16.1% |
| 2022 Q3 | -65.79 Million NOK | 11.97% |
| 2022 Q1 | -91.93 Million NOK | 18.84% |
| 2022 FY | -55.19 Million NOK | 51.27% |
| 2021 Q2 | -145.56 Million NOK | 11.13% |
| 2021 Q1 | -163.79 Million NOK | 12.17% |
| 2021 Q4 | -113.27 Million NOK | 15.15% |
| 2021 Q3 | -133.5 Million NOK | 8.29% |
| 2021 FY | -113.27 Million NOK | 39.26% |
| 2020 Q4 | -186.49 Million NOK | 10.97% |
| 2020 Q1 | -257.03 Million NOK | 0.68% |
| 2020 Q2 | -230.47 Million NOK | 10.33% |
| 2020 Q3 | -209.48 Million NOK | 9.11% |
| 2020 FY | -186.49 Million NOK | 27.93% |
| 2019 Q1 | -326.93 Million NOK | 6.22% |
| 2019 Q2 | -300.11 Million NOK | 8.2% |
| 2019 Q3 | -282.98 Million NOK | 5.71% |
| 2019 Q4 | -258.78 Million NOK | 8.55% |
| 2019 FY | -258.78 Million NOK | 25.77% |
| 2018 Q2 | -28.4 Million NOK | 26.39% |
| 2018 Q1 | -38.58 Million NOK | 23.13% |
| 2018 Q4 | -348.62 Million NOK | -1597.64% |
| 2018 FY | -348.62 Million NOK | -594.52% |
| 2018 Q3 | -20.53 Million NOK | 27.7% |
| 2017 Q3 | -53.75 Million NOK | 11.44% |
| 2017 Q2 | -60.7 Million NOK | 13.2% |
| 2017 Q1 | -69.92 Million NOK | -420.58% |
| 2017 FY | -50.19 Million NOK | -273.68% |
| 2017 Q4 | -50.19 Million NOK | 6.62% |
| 2016 Q2 | -31.02 Million NOK | 21.72% |
| 2016 Q1 | -39.63 Million NOK | 18.59% |
| 2016 Q3 | -20.66 Million NOK | 33.41% |
| 2016 Q4 | -13.43 Million NOK | 34.99% |
| 2016 FY | -13.43 Million NOK | 72.41% |
| 2015 Q1 | -71.83 Million NOK | -373.16% |
| 2015 FY | -48.68 Million NOK | -220.7% |
| 2015 Q3 | -53.89 Million NOK | 14.88% |
| 2015 Q2 | -63.31 Million NOK | 11.86% |
| 2015 Q4 | -48.68 Million NOK | 9.66% |
| 2014 FY | -15.18 Million NOK | 67.07% |
| 2014 Q4 | -15.18 Million NOK | 22.72% |
| 2014 Q2 | -29.18 Million NOK | 24.05% |
| 2014 Q3 | -19.64 Million NOK | 32.69% |
| 2014 Q1 | -38.43 Million NOK | 16.64% |
| 2013 Q2 | -59.6 Million NOK | 10.15% |
| 2013 Q3 | -52.52 Million NOK | 11.88% |
| 2013 Q4 | -46.1 Million NOK | 12.22% |
| 2013 FY | -46.1 Million NOK | 36.51% |
| 2013 Q1 | -66.34 Million NOK | 8.64% |
| 2012 Q1 | -90.29 Million NOK | 3.23% |
| 2012 Q2 | -85.9 Million NOK | 4.86% |
| 2012 FY | -72.62 Million NOK | 22.17% |
| 2012 Q3 | -73.02 Million NOK | 14.99% |
| 2012 Q4 | -72.62 Million NOK | 0.56% |
| 2011 FY | -93.31 Million NOK | 13.84% |
| 2011 Q1 | -106.27 Million NOK | 1.87% |
| 2011 Q3 | -98.79 Million NOK | 3.62% |
| 2011 Q2 | -102.5 Million NOK | 3.54% |
| 2011 Q4 | -93.31 Million NOK | 5.55% |
| 2010 Q3 | -105.28 Million NOK | -0.39% |
| 2010 Q2 | -104.87 Million NOK | 0.0% |
| 2010 FY | -108.3 Million NOK | -202.33% |
| 2010 Q4 | -108.3 Million NOK | -2.87% |
| 2009 FY | -35.82 Million NOK | 28.56% |
| 2009 Q4 | -35.68 Million NOK | 0.0% |
| 2008 FY | -50.14 Million NOK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Arctic Bioscience AS | -77.55 Million NOK | 47.309% |
| Aqua Bio Technology ASA | -5.82 Million NOK | -601.074% |
| ArcticZymes Technologies ASA | -237.27 Million NOK | 82.778% |
| BerGenBio ASA | -155.55 Million NOK | 73.73% |
| Hofseth BioCare ASA | 112.89 Million NOK | 136.195% |
| Thor Medical ASA | -41.28 Million NOK | 1.017% |
| Ultimovacs ASA | -262.84 Million NOK | 84.453% |